Literature DB >> 9542325

Pathogenesis, etiology and epidemiology of myelodysplastic syndromes.

C Aul1, D T Bowen, Y Yoshida.   

Abstract

BACKGROUND AND
OBJECTIVE: The myelodysplastic syndromes are common hematological malignancies affecting predominantly elderly people. Patients usually present with chronic cytopenias which gradually worsen due to progressive bone marrow failure or transformation into acute myeloid leukemia. Disease prevention is more cost-effective than therapeutic intervention and the establishment of the etiology and pathogenesis of MDS therefore assumes considerable importance. This review will outline current concepts of the pathobiology of MDS, putative etiological insults and the mechanisms of disease initiation as well as recent contributions to the descriptive epidemiology of these disorders. EVIDENCE AND INFORMATION SOURCES: The authors of the present review have a long-standing interest in the pathogenesis, etiology and epidemiology of MDS. Journal articles covered by the Science Citation Index and Medline have been reviewed and personal experience and discussion with international experts collated. STATE OF THE ART AND PERSPECTIVES: The initiation processes for the development of MDS remain unknown. A poorly defined transforming event affects a pluripotent or multipotent progenitor cell in the bone marrow, conferring a growth advantage upon it and eventually establishing clonal hematopoiesis. An important pathogenetic mechanism in MDS is premature intramedullary cell death via excessive apoptosis, explaining the apparent paradox of a cellular marrow in combination with peripheral cytopenias (ineffective hematopoiesis). Therapy-related MDS/AML following exposure to alkylating agents is the only clear etiological factor thus identified. Increasing evidence for exposure to benzene and radiation and the development of MDS is emerging. Benzene hematotoxicity is mediated via both genotoxic and non-genotoxic mechanisms, leading to aplasia, apoptosis and initiation (via genetic mutation) of clonal disorders such as MDS. Further studies of benzene hematotoxicity and therapy-related MDS should provide models for the elucidation of initiation events in MDS pathogenesis. The importance of such studies is emphasized by the rising frequency of MDS which largely reflects improved diagnostic criteria, increased physician awareness and extended use of diagnostic procedures in the elderly. Demographic changes will lead to a marked increase in MDS over the next few decades.

Entities:  

Mesh:

Year:  1998        PMID: 9542325

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  32 in total

1.  Deferasirox is a powerful NF-kappaB inhibitor in myelodysplastic cells and in leukemia cell lines acting independently from cell iron deprivation by chelation and reactive oxygen species scavenging.

Authors:  Emanuela Messa; Sonia Carturan; Chiara Maffè; Marisa Pautasso; Enrico Bracco; Antonella Roetto; Francesca Messa; Francesca Arruga; Ilaria Defilippi; Valentina Rosso; Chiara Zanone; Antonia Rotolo; Elisabetta Greco; Rosa M Pellegrino; Daniele Alberti; Giuseppe Saglio; Daniela Cilloni
Journal:  Haematologica       Date:  2010-06-09       Impact factor: 9.941

2.  [Myelodysplastic syndromes].

Authors:  A Giagounidis
Journal:  Internist (Berl)       Date:  2013-06       Impact factor: 0.743

Review 3.  Impact of growth factors in the regulation of apoptosis in low-risk myelodysplastic syndromes.

Authors:  R Tehranchi
Journal:  Med Oncol       Date:  2006       Impact factor: 3.064

Review 4.  Important features of myelodysplastic syndrome.

Authors:  Wolf K Hofmann; H Phillip Koeffler
Journal:  Int J Hematol       Date:  2002-08       Impact factor: 2.490

5.  Prospective cardiac magnetic resonance imaging survey in myelodysplastic syndrome patients: insights from an Italian network.

Authors:  Alessia Pepe; Michele Rizzo; Sara Galimberti; Claudia Baratè; Esther Natalie Oliva; Francesco Arcioni; Sergio Storti; Stefania Renne; Massimo Midiri; Gennaro Restaino; Vincenzo Positano; Maurizio Mangione; Antonella Meloni
Journal:  Ann Hematol       Date:  2021-03-19       Impact factor: 3.673

6.  [Myelodysplastic syndromes].

Authors:  C Aul; A Giagounidis; U Germing
Journal:  Internist (Berl)       Date:  2010-02       Impact factor: 0.743

7.  Gene expression patterns in myelodyplasia underline the role of apoptosis and differentiation in disease initiation and progression.

Authors:  Merav Bar; Derek Stirewalt; Era Pogosova-Agadjanyan; Vitas Wagner; Ted Gooley; Nissa Abbasi; Ravi Bhatia; H Joachim Deeg; Jerald Radich
Journal:  Transl Oncogenomics       Date:  2008-05-29

8.  Iron chelation therapy in myelodysplastic syndromes.

Authors:  Emanuela Messa; Daniela Cilloni; Giuseppe Saglio
Journal:  Adv Hematol       Date:  2010-06-20

9.  Identification of protein-coding and non-coding RNA expression profiles in CD34+ and in stromal cells in refractory anemia with ringed sideroblasts.

Authors:  Mariana O Baratti; Yuri B Moreira; Fabiola Traina; Fernando F Costa; Sergio Verjovski-Almeida; Sara T Olalla-Saad
Journal:  BMC Med Genomics       Date:  2010-07-15       Impact factor: 3.063

10.  Models of granulocyte DNA structure are highly predictive of myelodysplastic syndrome.

Authors:  Donald C Malins; Katie M Anderson; Nayak L Polissar; Gary K Ostrander; Edward T Knobbe; Virginia M Green; Naomi K Gilman; Jerry L Spivak
Journal:  Proc Natl Acad Sci U S A       Date:  2004-03-29       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.